Augusto Miravalle

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

Augusto Miravalle, Rikke Beck Jensen, R. Philip Kinkel · Archives of Neurology · 2010 · 174 citations

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

Jonathan D. Campbell, Vahram Ghushchyan, R. Brett McQueen et al. · Multiple Sclerosis and Related Disorders · 2013 · 127 citations

Quality Of Life, Indirect Costs, Health Policy +12

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Luca Prosperini, Revere P. Kinkel, Augusto Miravalle et al. · Therapeutic Advances in Neurological Disorders · 2019 · 95 citations · Full text

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

Robert J. Fox, Christopher S. Coffey, Merit Cudkowicz et al. · Contemporary Clinical Trials · 2016 · 66 citations · Full text

Neurological Disorder, Clinical Neurology, Clinical Trials +6